高级检索
当前位置: 首页 > 详情页

MicroRNA-142-5p Suppresses Proliferation and Invasion of Non-Small Cell Lung Cancer Cells by Targeting Programmed Cell Death Receptor Ligand 1

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Traditional Chinese Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, [2]Department of Pathology, Xuyi People's Hospital Jiangsu Province, Huai’an 211700, China
出处:
ISSN:

关键词: Non-small cell lung cancer microRNA-142-5p programmed cell death receptor ligand 1 proliferation immunity

摘要:
Lung cancer is one of the most deadly tumor disease in the world and most lung cancer is non-small cell lung cancer. MicroRNAs are considered as a variety of endogenous non-coding RNA, acting as interference during the process after transcription of gene. Recently, microRNA-142-5p, one of the microRNAs, was reported to enhance anti-tumor immune of non-small cell lung cancer cells by targeting programmed cell death receptor ligand 1. Programmed cell death receptor ligand 1 was also believed to be a regulator of cell proliferation and migration. However, the effect of microRNA-142-5p on proliferation and invasion of non-small cell lung cancer cells via regulating programmed cell death receptor ligand 1 was still unknown. Thus, this study demonstrated that there was low expression level of microRNA-142-5p in different nonsmall cell lung cancer cell lines. Programmed cell death receptor ligand 1 was proved to be the target gene of microRNA-142-5p and microRNA-142-5p also had negative correlation with programmed cell death receptor ligand 1. The high expression of microRNA-142-5p lead to suppression of proliferation and invasion in non-small cell lung cancer cells by down regulation of programmed cell death receptor ligand 1. The mechanism of microRNA-142-5p affecting proliferation and invasion of non-small cell lung cancer cells via targeting programmed cell death receptor ligand 1 might give a new thought of tumor therapy.

语种:
WOS:
中科院分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 药学
最新[2025]版:
JCR分区:
出版当年[2021]版:
Q4 PHARMACOLOGY & PHARMACY
最新[2024]版:

影响因子: 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Department of Traditional Chinese Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011,
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42314 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号